Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.40 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403908 | 0.91 | HCRTR2 (0.42) | HTR1ASLC6A4HCRTR2MPO | |
| SCHEMBL2408924 | 0.90 | HTR1A (0.42) | HTR1ASLC6A4HCRTR2MPO | |
| SCHEMBL2406278 | 0.89 | HCRTR2 (0.41) | HTR1ASLC6A4HCRTR2MPO | |
| SCHEMBL2405180 | 0.89 | HCRTR2 (0.42) | HTR1ASLC6A4HCRTR2HCRTR1MPO | |
| SCHEMBL2404386 | 0.89 | HTR1A (0.41) | HTR1ASLC6A4HCRTR2MPO | |
| SCHEMBL2406980 | 0.88 | MPO (0.41) | HTR1ASLC6A4HCRTR2MPO | |
| SCHEMBL2406633 | 0.85 | HTR1A (0.43) | HTR1ASLC6A4MPO | |
| SCHEMBL2403179 | 0.85 | HTR1A (0.43) | HTR1ASLC6A4HCRTR2HCRTR1MPO | |
| SCHEMBL2410549 | 0.85 | HCRTR1 (0.46) | HTR1AHCRTR2HCRTR1 | |
| SCHEMBL2404244 | 0.84 | HCRTR2 (0.48) | HTR1AHCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HTR1A 56/4885SLC6A4 781/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.